27-Study Review Bolsters High-Dose iNO’s Broad-Spectrum Antimicrobial Potential
Beyond Air highlighted 27 studies showing high-dose inhaled nitric oxide above 20 ppm delivers broad-spectrum antimicrobial effects—microbial killing, biofilm disruption, antiviral action and enhanced mucociliary clearance. The paper outlines future research in hospital-acquired and ventilator-associated pneumonia, tuberculosis and immunocompromised patients, potentially accelerating Beyond Air’s LungFit development.
1. Independent Review Findings
The narrative review synthesizes clinical and mechanistic data from 27 studies evaluating high-dose inhaled nitric oxide administered at concentrations above the FDA-approved 20 ppm. It highlights evidence of safe delivery in hospital and home settings, encompassing early-phase trials in pneumonia, COVID-19, bronchiolitis and nontuberculous mycobacteria.
2. Multimodal Antimicrobial Actions
The review details multiple antimicrobial mechanisms of high-dose iNO, including direct microbial killing, disruption of biofilms, antiviral properties, reduction of inflammation and enhanced mucociliary clearance. These multimodal effects suggest potential efficacy against pathogens and infections resistant to standard treatments.
3. Future Research Roadmap
Authors propose a research roadmap targeting hospital-acquired pneumonia, ventilator-associated pneumonia, tuberculosis, post-viral fibrosis and immunocompromised patients. This roadmap underscores areas where novel therapies are urgently needed and where high-dose iNO could fill existing treatment gaps.
4. Implications for Beyond Air
Beyond Air expects the review to catalyze new studies and accelerate clinical development of its LungFit systems, which can deliver up to 80 ppm of nitric oxide without cylinders. The company’s LungFit PH is already approved, while other LungFit variants remain in investigational trials for severe lung infections.